Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -2.26%9.54B | 11.59%41.35B | 10.44%30.74B | 5.42%19.98B | 0.94%9.76B | 1.73%37.05B | 2.20%27.84B | 4.01%18.95B | 4.93%9.66B | 13.67%36.42B |
| Special items of operating revenue | -12.00%3.47M | ---- | 30.55%22.36M | ---- | -24.49%3.94M | ---- | -13.66%17.13M | ---- | -3.92%5.22M | ---- |
| Operating income | -2.26%9.54B | 11.59%41.35B | 10.45%30.77B | 5.42%19.98B | 0.93%9.76B | 1.73%37.05B | 2.19%27.86B | 4.01%18.95B | 4.92%9.67B | 13.67%36.42B |
| Cost of sales | ---- | -14.41%-32.26B | ---- | -6.22%-15.33B | ---- | 2.16%-28.2B | ---- | -1.46%-14.43B | ---- | -12.39%-28.82B |
| Operating expenses | -3.11%-7.7B | -14.41%-32.26B | -11.69%-23.62B | -6.22%-15.33B | -1.50%-7.47B | 2.16%-28.2B | 1.20%-21.15B | -1.46%-14.43B | -1.05%-7.36B | -12.39%-28.82B |
| Special items of gross profit | 12.00%-3.47M | ---- | -30.55%-22.36M | ---- | 24.49%-3.94M | ---- | 13.66%-17.13M | ---- | 3.92%-5.22M | ---- |
| Gross profit | -19.77%1.84B | 2.58%9.08B | 6.47%7.12B | 2.87%4.65B | -0.81%2.29B | 16.46%8.85B | 14.65%6.69B | 13.05%4.52B | 19.55%2.31B | 18.81%7.6B |
| Selling expenses | 4.20%-225.34M | 15.70%-901.54M | 3.59%-667.26M | 10.98%-420.36M | 5.64%-235.23M | -17.47%-1.07B | 7.74%-692.09M | 22.46%-472.19M | 0.88%-249.3M | -9.47%-910.38M |
| Administrative expenses | -23.22%-374.53M | -2.66%-1.53B | -16.35%-1.02B | -10.15%-622.65M | -6.70%-303.95M | -24.52%-1.49B | -3.99%-880.86M | -8.01%-565.26M | -7.71%-284.86M | -11.80%-1.2B |
| Research and development expenses | 2.43%-366.62M | -9.32%-1.66B | -1.55%-1.23B | 2.45%-813.48M | 19.51%-375.77M | 3.30%-1.52B | 6.86%-1.21B | -0.71%-833.93M | -10.62%-466.83M | -13.15%-1.57B |
| Profit from asset sales | 96,581.81%161.57M | ---- | -4.68%6.64M | ---- | -93.22%167.12K | ---- | 106.81%6.97M | ---- | 170.28%2.47M | ---- |
| Revaluation surplus | -114.11%-2.76M | ---- | 418.66%356.29M | ---- | -41.75%19.56M | ---- | -15.54%68.69M | ---- | -18.14%33.58M | ---- |
| -Changes in the fair value of other assets | -114.11%-2.76M | ---- | 418.66%356.29M | ---- | -41.75%19.56M | ---- | -15.54%68.69M | ---- | -18.14%33.58M | ---- |
| Impairment and provision | 135.33%29.11M | -157.41%-405.98M | 4.52%-260.72M | -33.26%-196.17M | -89.29%-82.39M | -407.89%-157.72M | -467.10%-273.06M | -620.42%-147.21M | -69.64%-43.53M | 137.31%51.23M |
| -Other impairment is provision | 135.33%29.11M | -157.41%-405.98M | 4.52%-260.72M | -33.26%-196.17M | -89.29%-82.39M | -407.89%-157.72M | -467.10%-273.06M | -620.42%-147.21M | -69.64%-43.53M | 137.31%51.23M |
| Operating interest expense | 49.10%-1.21M | ---- | 42.49%-4.64M | ---- | -4.77%-2.38M | ---- | 26.41%-8.07M | ---- | 32.84%-2.28M | ---- |
| Special items of operating profit | -1.57%142.75M | -13.78%723.26M | -36.26%353.35M | 25.92%544.39M | -19.68%145.03M | 75.16%838.86M | 87.85%554.35M | 29.26%432.33M | 68.99%180.56M | 34.38%478.91M |
| Operating profit | -17.90%1.16B | -2.72%5.31B | 8.92%4.52B | 7.08%3.15B | -2.18%1.41B | 22.47%5.45B | 27.55%4.15B | 24.72%2.94B | 34.92%1.45B | 33.86%4.45B |
| Financing income | 23.61%18.88M | ---- | -35.28%45.45M | ---- | -40.81%15.28M | ---- | -22.43%70.22M | ---- | -12.85%25.81M | ---- |
| Financing cost | 19.32%-45.92M | 24.34%-225.43M | 17.58%-158.97M | 7.25%-126.91M | 23.81%-56.92M | 23.33%-297.95M | 24.20%-192.87M | 18.82%-136.82M | 4.49%-74.7M | -46.42%-388.6M |
| Share of profits of associates | ---- | -25.95%35.78M | ---- | -42.31%17.89M | ---- | 2.88%48.32M | ---- | 32.95%31M | ---- | 102.90%46.97M |
| Share of profit from joint venture company | ---- | -20.49%5.04M | ---- | -71.47%1.3M | ---- | 7.55%6.34M | ---- | 911.28%4.57M | ---- | 16.65%5.89M |
| Special items of earning before tax | 2,771.15%19.48M | ---- | -77.45%2.7M | ---- | -164.91%-729.42K | ---- | 201.36%11.95M | ---- | -48.34%1.12M | ---- |
| Earning before tax | -19.14%1.1B | -1.72%5.12B | 8.86%4.36B | 7.10%3.04B | -2.56%1.36B | 26.55%5.21B | 27.02%4B | 28.31%2.84B | 34.73%1.39B | 33.27%4.12B |
| Tax | ---- | 23.38%-751.31M | ---- | 5.96%-456.8M | ---- | -59.01%-980.57M | ---- | -29.66%-485.76M | ---- | -33.46%-616.67M |
| After-tax profit from continuing operations | -16.49%933.29M | 3.30%4.37B | 11.74%3.7B | 9.80%2.58B | -4.73%1.12B | 20.83%4.23B | 25.58%3.32B | 28.03%2.35B | 35.45%1.17B | 33.24%3.5B |
| Earning after tax | -16.49%933.29M | 3.30%4.37B | 11.74%3.7B | 9.80%2.58B | -4.73%1.12B | 20.83%4.23B | 25.58%3.32B | 28.03%2.35B | 35.45%1.17B | 33.24%3.5B |
| Minority profit | 42.64%41.18M | -77.59%64.4M | -76.80%59.58M | -69.45%53.79M | -77.95%28.87M | 43.52%287.41M | 48.64%256.76M | 35.49%176.05M | 57.79%130.93M | 123.08%200.26M |
| Profit attributable to shareholders | -18.06%892.1M | 9.20%4.31B | 19.17%3.64B | 16.22%2.53B | 4.47%1.09B | 19.45%3.94B | 23.97%3.06B | 27.46%2.17B | 33.08%1.04B | 30.06%3.3B |
| Basic earnings per share | -16.50%0.511 | 10.76%2.4546 | 20.57%2.075 | 16.26%1.43 | 4.08%0.612 | 18.37%2.2162 | 22.93%1.721 | 26.80%1.23 | 31.84%0.588 | 28.78%1.8722 |
| Diluted earnings per share | -17.32%0.506 | 10.64%2.4458 | 20.93%2.074 | 17.21%1.43 | 4.62%0.612 | 18.79%2.2106 | 22.76%1.715 | 25.77%1.22 | 32.05%0.585 | 28.74%1.8609 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion |
| Auditor | -- | Deloitte Touche Tohmatsu会计师事务所 | -- | -- | -- | Deloitte Touche Tohmatsu会计师事务所 | -- | -- | -- | PwC |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.